SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004; 351: 1860-1873.
  • 2
    Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma. 2009; 9: 278-288.
  • 3
    Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996; 335: 91-97.
  • 4
    Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348: 1875-1883.
  • 5
    Kazmi SM, Saliba RM, Donato M, et al. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant. 2011; 46: 510-515.
  • 6
    Anagnostopoulos A, Aleman A, Ayers G, et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer. 2004; 100: 2607-2612.
  • 7
    Moreau P, Facon T, Attal M, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002; 99: 731-735.
  • 8
    Christoforidou AV, Saliba RM, Williams P, et al. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant. 2007; 13: 543-549.
  • 9
    Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348: 2609-2617.
  • 10
    Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352: 2487-2498.
  • 11
    Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009; 27: 5713-5719.
  • 12
    Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003; 9: 1136-1144.
  • 13
    Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003; 101: 2377-2380.
  • 14
    San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359: 906-917.
  • 15
    Roussel M, Moreau P, Huynh A, et al; Intergroupe Francophone du Myelome (IFM). Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood. 2010; 15: 32-37.
  • 16
    Qazilbash MH, Saliba RM, Nieto Y, et al. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008; 14: 1401-1407.
  • 17
    Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20: 1467-1473.
  • 18
    Badros AZ. In the age of novel therapies, what defines high-risk multiple myeloma? J Natl Compr Canc Netw. 2010; 8( suppl 1): S28-S34.
  • 19
    Snedecor GWC, Cochran WG. Statistical Methods. 7th ed. Ames, Iowa: Iowa State University Press; 1980.
  • 20
    Fischer R. On the interpretation of x2 from contingency tables, and the calculation of P. J R Stat Soc. 1922; 85: 87-94.
  • 21
    Randles R, Wolfe DA. Introduction to the Theory of Nonparametric Statistics: New York: John Wiley & Sons, Inc.; 1979.
  • 22
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457-481.
  • 23
    Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50: 163-170.
  • 24
    Ibrahim JG, Chen MH, Sinha D. Bayesian Survival Analysis. New York: Springer; 2001.
  • 25
    Schwarz GE. Estimating the dimension of a model. Ann Stat. 1978; 6: 461-464.
  • 26
    Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011; 117: 4696-4700.
  • 27
    Thomas A, O'Hara B, Ligges U, Sturtz S. Making BUGS open. R News. 2006: 12-17.
  • 28
    Dimopoulos MA, Weber D, Kantarjian H, Delasalle KB, Alexanian R. Hyper-CVAD for VAD-resistant multiple myeloma. Am J Hematol. 1996; 52: 77-81.
  • 29
    Lonial S, Kaufman J, Tighiouart M, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res. 2010; 16: 5079-5086.
  • 30
    Qazilbash MH, Saliba R, De Lima M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer. 2006; 106: 1084-1089.
  • 31
    Harvey RD, Nettles J, Wang B, Sun SY, Lonial S. Commentary on Perrone, et al. “vitamin C: not for breakfast anymore. if you have myeloma.” Leukemia. 2009; 23: 1939-1940.
  • 32
    Perrone G, Hideshima T, Ikeda H, et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia. 2009; 23: 1679-1686.